Table 3 Pairwise comparisons of adjacent tumor stages for American Joint Committee on Cancer and Vanderbilt staging systems for retroperitoneal sarcoma

From: The Vanderbilt staging system for retroperitoneal sarcoma: a validation study of 6857 patients from the National Cancer Database

Comparison

HR (95% CI)

P

AJCC 8th Ed. (n = 6236)

 Stage IB vs IA

1.04 (0.69–1.56)

1.000

 Stage II vs IB

1.97 (1.53–2.56)

<0.0005

 Stage IIIA vs II

1.01 (0.77–1.31)

1.000

 Stage IIIB vs IIIA

1.35 (1.16–1.57)

<0.0005

 Stage IV vs IIIB

2.18 (1.88–2.53)

<0.0005

AJCC 7th Ed. (n = 6507)

 Stage IB vs IA

1.10 (0.72–1.67)

0.98

 Stage IIA vs IB

1.93 (1.49–2.49)

<0.0005

 Stage IIB vs IIA

0.85 (0.65–1.11)

0.45

 Stage III vs IIB

1.78 (1.54–2.06)

<0.0005

 Stage IV vs III

1.99 (1.71–2.30)

<0.0005

Vanderbilt System (n = 6140)

 Stage IB vs IA

1.23 (0.92–1.64)

0.29

 Stage II vs IB

1.86 (1.56–2.23)

<0.0005

 Stage IIIA vs II

1.41 (1.23–1.63)

<0.0005

 Stage IIIB vs IIIA

1.36 (1.18–1.56)

<0.0005

 Stage IV vs IIIB

1.98 (1.65–2.38)

<0.0005

  1. CI confidence interval, HR hazard ratio
Back to article page